Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-01-22

FDA Approved: SAPHRIS — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

The FDA approved Allergan's supplemental application for SAPHRIS (asenapine), resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Saphris (asenapine)

Snippet

SUPPL AP for SAPHRIS (ASENAPINE MALEATE)